Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Won-Mook | - |
dc.contributor.author | Kim, Gi-Ae | - |
dc.contributor.author | Choi, Jonggi | - |
dc.contributor.author | Han, Seungbong | - |
dc.contributor.author | Lim, Young-Suk | - |
dc.date.accessioned | 2022-08-26T02:40:54Z | - |
dc.date.available | 2022-08-26T02:40:54Z | - |
dc.date.created | 2022-08-25 | - |
dc.date.issued | 2022-05-16 | - |
dc.identifier.issn | 0021-9738 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/143417 | - |
dc.description.abstract | BACKGROUND. It is unclear whether the level of serum hepatitis B virus (HBV) DNA at baseline affects the on-treatment risk of hepatocellular carcinoma (HCC) in hepatitis B e antigen-positive (HBeAg-positive), noncirrhotic patients with chronic hepatitis B (CHB). METHODS. We conducted a multicenter cohort study including 2073 entecavir- or tenofovir-treated, HBeAg-positive, noncirrhotic adult CHB patients with baseline HBV DNA levels of 5.00 log(10) IU/mL or higher at 3 centers in South Korea between January 2007 and December 2016. We evaluated the on-treatment incidence rate of HCC according to baseline HBV DNA levels. RESULTS. During a median 5.7 years of continuous antiviral treatment, 47 patients developed HCC (0.39 per 100 personyears). By Kaplan-Meier analysis, the risk of HCC was lowest in patients with baseline HBV DNA levels of 8.00 log(10) IU/mL or higher, increased incrementally with decreasing viral load, and was highest in those with HBV DNA levels of 5.00-5.99 log(10) IU/mL (P < 0.001). By multivariable analysis, the baseline HBV DNA level was an independent factor that was inversely associated with HCC risk. Compared with HBV DNA levels of 8.00 log(10) IU/mL or higher, the adjusted HRs for HCC risk with HBV DNA levels of 7.00-7.99 log(10) IU/mL, 6.00-6.99 log(10) IU/mL, or 5.00-5.99 log(10) IU/mL were 2.48 (P = 0.03), 3.69 (P = 0.002), and 6.10 (P < 0.001), respectively. CONCLUSION. On-treatment HCC risk increased incrementally with decreasing baseline HBV DNA levels in the range of 5.00 log(10) IU/mL or higher in HBeAg-positive, noncirrhotic adult patients with CHB. Early initiation of antiviral treatment when the viral load is high (>= 8.00 log(10) IU/mL) may maintain the lowest risk of HCC for those patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER SOC CLINICAL INVESTIGATION INC | - |
dc.subject | CLINICAL-PRACTICE GUIDELINES | - |
dc.subject | ALANINE AMINOTRANSFERASE | - |
dc.subject | GLOBAL ELIMINATION | - |
dc.subject | HBV DNA | - |
dc.subject | VIRUS | - |
dc.subject | LIVER | - |
dc.subject | MANAGEMENT | - |
dc.subject | CANCER | - |
dc.subject | EPIDEMIOLOGY | - |
dc.subject | HEPATOCYTES | - |
dc.title | Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Seungbong | - |
dc.identifier.doi | 10.1172/JCI154833 | - |
dc.identifier.scopusid | 2-s2.0-85129866951 | - |
dc.identifier.wosid | 000800758200002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL INVESTIGATION, v.132, no.10 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL INVESTIGATION | - |
dc.citation.title | JOURNAL OF CLINICAL INVESTIGATION | - |
dc.citation.volume | 132 | - |
dc.citation.number | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE GUIDELINES | - |
dc.subject.keywordPlus | ALANINE AMINOTRANSFERASE | - |
dc.subject.keywordPlus | GLOBAL ELIMINATION | - |
dc.subject.keywordPlus | HBV DNA | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | LIVER | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | HEPATOCYTES | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.